Finding the Missing $200K – $450K: The Orphan Drug Blind Spot in 340B | Lisa Nezneski

Are your 340B operations fully optimized, or are you secretly missing massive savings? In this episode of 340B Pulse, Lisa Nezneski, Founder of 340B Orphan Drug Solutions, explains the "Orphan Drug Blind Spot." Many rural and community hospitals mistakenly assume orphan drugs are strictly excluded from their programs, but discretionary manufacturer pricing can unlock $200K to $450K in hidden revenue for your hospital every year.If an executive asked you right now if your hospital was fully maximizing its 340B savings, your answer would probably be "Yes." But if you operate a Critical Access Hospital (CAH), a Sole Community Hospital (SCH), or a Rural Referral Center (RRC), your program might still be leaving hundreds of thousands of dollars on the table. Join hosts Mohamed Atif and Salman Asif as they sit down with 340B veteran Lisa Rizenki to unpack this massive, widely misunderstood opportunity. This operational deep-dive reveals why orphan drugs routinely make up 50% to 75% of your total drug budget, the truth about discretionary manufacturer discounts, and why your Third-Party Administrator (TPA) might be automatically blocking these life-changing accumulations.Discover how to safely run a "first-pass" validation without disrupting operations, reframe the discovery of missing savings for hospital administration, and ultimately turn regulatory complexity into a predictable strategy that funds vital community health programs.Subscribe to 340B Pulse for more operator-level conversations on program compliance, hospital finance, and healthcare technology!00:00 - Introduction to 340B Pulse & Today's Topic01:45 - What is the 340B Orphan Drug Blind Spot?06:43 - The Discretionary Pricing Misconception Explained13:35 - The 50% Rule & Avoiding The $75,000 Weekend Mistake18:10 - Identifying TPA Bottlenecks & Accumulator Setup Issues26:57 - The Secret to Pitching Administrators & The CFO28:05 - Why Pharmacists Must Learn to Sell32:19 - The "Bless Your Heart" TPA Software Blocker Story38:50 - The $450,000 Success Story (Case Study)49:04 - The $200 vs. $2 Gleevec Pricing Reality50:37 - Overcoming the Fear of Finding "Missed" Savings (Becoming the Hero)53:30 - Final Thoughts & Closing ActionsWhat is the 340B Orphan Drug Blind Spot? Many Critical Access and Sole Community Hospitals mistakenly assume orphan drugs are strictly excluded from their 340B programs and cannot receive discounts. In reality, manufacturers often offer discretionary discounts that hospitals fail to claim, leaving significant money on the table.How much in savings are hospitals missing from orphan drugs?On average, audits reveal that hospitals frequently miss between $200,000 and $450,000 annually due to misconfigured TPA setups and blocked accumulations regarding orphan drug claims.How can a hospital fix missed orphan drug savings?Covered Entities can recapture these savings by utilizing tracking tools like the 340B Orphan Drug Estimator, directly managing IT communication queues with TPAs, and properly routing NDCs to align with discretionary manufacturer pricing.#340B #OrphanDrugs #HospitalFinance #HealthcareOperations #PharmacyBenefitManager #HealthcareTech #RuralHealth #CriticalAccessHospital #340BPulse #NorthArcHealth